Regeneron Pharmaceuticals Inc. and partner Sanofi SA are hoping now to make their case in the Federal Circuit after a U.S. District Court jury ruled that patents covering Amgen Inc.'s competing PCSK9 antibody, Repatha (evolocumab), are valid, a decision that, if it stands, could put Regeneron and Sanofi on the hook for damages, including royalties from sales of Praluent (alirocumab).